DK Stock Recent News
DK LATEST HEADLINES
The hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to keep up with demand.
Delek US (DK) projects $350 million in capital expenditures for the full-year 2023. It expects to spend $202 million on Refining, $81 million on Logistics, $31 million on Retail and $36 million on Corporate/Other.
The headline numbers for Delek US Holdings (DK) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Delek US Holdings (DK) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.58 per share a year ago.
BRENTWOOD, Tenn. , April 6, 2023 /PRNewswire/ -- Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced that the Partnership intends to issue a press release summarizing first quarter 2023 results before the U.S. stock market opens on Monday, May 8, 2023.
BRENTWOOD, Tenn. , April 6, 2023 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) ("Delek US") today announced that the Company intends to issue a press release summarizing first quarter 2023 results before the U.S. stock market opens on Monday, May 8, 2023.
Three small stocks, SL Green Realty Corp. (NYSE: SLG), Delek US Holdings Inc. (NYSE: DK), and Hudson Pacific Properties Inc. (NYSE: HPP) are among the stocks on MarketBeat's Top-Rated Small Caps screen.
Delek US Holdings (DK) reported earnings 30 days ago. What's next for the stock?
Delek (DK) plans a $350 million capex and process improvement to achieve an annual run rate of $90-$100 million, possibly through lower costs or better markets.
Delek US Holdings (DK) delivered earnings and revenue surprises of 7.32% and 14.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?